Detalhe da pesquisa
1.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw
; 22(1): 4-16, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394781
2.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Lancet Oncol
; 24(5): 553-562, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011650
3.
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Lancet Oncol
; 24(6): 669-681, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37187202
4.
Phase II Study of Cabozantinib in Patients With Bone Metastasis.
Oncologist
; 27(7): 600-606, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35524758
5.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(1): 71-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991070
6.
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
J Natl Compr Canc Netw
; 18(9): 1160-1170, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886895
7.
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Oncologist
; 24(6): 725-727, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036769
8.
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Oncologist
; 24(2): 202-210, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190302
9.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Oncologist
; 24(9): 1151-e817, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171735
10.
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Oncologist
; 24(11): 1497-1501, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31399500
11.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
J Natl Compr Canc Netw
; 17(11): 1278-1285, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31693980
12.
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(6): 804-834, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28596261
13.
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Lancet Oncol
; 16(15): 1473-1482, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26482279
14.
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Cancer
; 121(19): 3435-43, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26058385
15.
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Br J Cancer
; 113(11): 1571-80, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26492223
16.
The Art of Oncology: COVID-19 Era.
Oncologist
; 25(11): 997-1000g, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32697887
17.
Testicular Cancer, Version 2.2015.
J Natl Compr Canc Netw
; 13(6): 772-99, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26085393
18.
Kidney cancer, version 3.2015.
J Natl Compr Canc Netw
; 13(2): 151-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25691606
19.
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cancer
; 120(12): 1871-80, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24634003
20.
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
BJU Int
; 114(6b): E25-E31, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24298897